The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compoistions that stimulate anti-tumor immune responses. The present invention relates to 67 novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine composition for eliciting anti-tumor immune responses.本發明涉及免疫療法所使用的肽、核酸和細胞。特別是，本發明涉及癌症的免疫療法。本發明還涉及腫瘤相關性細胞毒殺T淋巴細胞(CTL)的肽表位(單用或與其它腫瘤相關性肽聯合使用)，以作為疫苗組合物中的活性藥物成分激發抗腫瘤免疫反應。本發明涉及67個新型肽序列，及其人腫瘤細胞HLA I類與HLA II類分子的衍生序列，以用於在疫苗組合物中引發抗腫瘤免疫反應。
